Preclinical efficacy testing of three antivenoms against Naja ashei venom-induced lethality

Mitchel Otieno Okumu; James Mucunu Mbaria; Joseph Kangangi Gikunju; Paul Gichohi Mbuthia; Vincent Odongo Madadi; Francis Okumu Ochola; Kenneth Narotso Maloba; Joseph Gichuki Nderitu

doi:10.1016/j.toxcx.2022.100124

Preclinical efficacy testing of three antivenoms against Naja ashei venom-induced lethality

Toxicon X. 2022 Apr 27:14:100124. doi: 10.1016/j.toxcx.2022.100124. eCollection 2022 Jun.

Authors

Mitchel Otieno Okumu¹, James Mucunu Mbaria¹, Joseph Kangangi Gikunju², Paul Gichohi Mbuthia³, Vincent Odongo Madadi⁴, Francis Okumu Ochola⁵, Kenneth Narotso Maloba¹, Joseph Gichuki Nderitu¹

Affiliations

¹ Department of Public Health, Pharmacology, and Toxicology, University of Nairobi, Kenya.
² Department of Medical Laboratory Science, Jomo Kenyatta University of Agriculture and Technology, Kenya.
³ Department of Veterinary Pathology, Microbiology, and Parasitology, University of Nairobi, Kenya.
⁴ Department of Chemistry, University of Nairobi, Kenya.
⁵ Department of Pharmacology and Toxicology, Moi University, Kenya.

Abstract

This study aimed to determine the efficacy of Inoserp, Vins bioproducts, and South African Institute of Medical Research (SAIMR) polyvalent antivenoms in neutralizing Naja ashei venom-induced lethality in mice. The neutralization efficacy of the antivenoms were expressed as effective dose, median effective ratio, potency, normalized potency, volume, and the number of vials of antivenom required to neutralize 100 mg of Naja ashei venom (NAV).

Keywords: Antivenoms; Naja ashei; Neutralization; Potency; Snakebite.